Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real-Life Experience From a National Reference Network
Diabetes Obes Metab. 2026 Aug 19. doi: 10.1111/dom.71126. Online ahead of print.ABSTRACTAIM: Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients

